霉酚酸酯循证治疗特发性膜性肾病合并肾病综合征1例报告

目的报告1例特发性膜性肾病(IMN)合并肾病综合征(NS)患者应用霉酚酸酯进行循证治疗的结果。方法计算机检索Cochrane(2005年第3期)、MEDLINE(1978～2006)和CNKI(1978～2006),查找霉酚酸酯治疗IMN合并NS及与病情缓解有关的系统评价、临床随机对照试验、队列研究和病例对照研究等,并对所获证据进行质量评价,进而应用于本例患者的临床治疗。结果现有C级临床证据表明,霉酚酸酯能提高IMN合并NS患者的蛋白尿缓解率,对激素或烷化剂耐药的患者也有一定疗效,但能否提高肾脏的长期存活率尚无可靠证据。据此,结合医生经验及患者意愿,对患者采取霉酚酸酯联合糖皮质激素治疗,按患者体重(50kg)使用霉酚酸酯2．0g／d和强的松25 mg/d,并同时给予活血化瘀及对症支持治疗,3月后患者蛋白尿有所缓解。目前仍在随访中。结论现有C级证据表明短期内霉酚酸酯能提高IMN合并NS患者的蛋白尿缓解率,但能否提高患者肾脏长期存活率以及卫生经济学评价有待进一步研究。

Evidence-based Treatment of Mycophenolate Mofetil for Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Case Report

Objective To report an evidence-based treatment of Mycophenolate Mofetil for idiopathic membranous nephropathy (IMN) with nephrotic syndrome (NS). Methods We searched The Cochrane Library (Issue 3, 2005), MEDLINE (1978 to 2006) and CNKI (1978 to 2006), and critically appraised the available evidence. Results The available Level C (low quality) evidence showed that Mycophenolate Mofetil was effective for the remission of proteinuria, and effective in patients who were resistant to steroid or cytotoxic agents. However, there was no evidence on its long-term effect on renal survival. Given the current evidence, together with our clinical experience and the patient' s preference, Mycophenolate Mofetil and glucocorticoid were administered to the patient. After 3 months of treatment, proteinuria was relieved. The patient is still can followed up. Conclusions We only find Level C evidence to support the short-term efficacy of Mycophenolate Mofetil on the remission of proteinuria. Further studies on its long-term effects on renal survival, and a health economics evaluation are needed.